Seers Technology, D&D Pharmatech, OliX, ABL Bio. Among the top 10 stocks by share price increase rate this year, four were ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals and ...

SEONGNAM, South Korea, February 10, 2025--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced a global licensing agreement with Eli ...

SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the first patient has been administered on June 5, in a ...

SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that it has received approval from the Human Research Ethics ...

OliX Pharmaceuticals, a bio company based on ribonucleic acid (RNA) interference technology, recorded the upper price limit following the market close on the 7th in after-hours transactions. This ...

SUWON, South Korea--(BUSINESS WIRE)--#KOSDAQ226950--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company presented its latest study ...

- Additional nonclinical study is ongoing to identify weight-managing efficacy of OLX75016-dual GIP/GLP-1 receptor agonists combi treatment SUWON, South Korea--(BUSINESS WIRE)--#GIP--OliX ...

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, ...

Dong Ki (DK) Lee, PhD, OliX’s Founder, CEO, and Chief Scientific Officer A South Korean developer of RNAi (RNA interference) therapeutics plans to expand its U.S. operations and advance up to ten ...

SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will ...